Author:
Lee Seon-Hyeong,Kim Nayeon,Kim Se-Jin,Song Jaewhan,Gong Young-Dae,Kim Soo-Youl
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference39 articles.
1. Caccamo D, Curro M, Ientile R (2010) Potential of transglutaminase 2 as a therapeutic target. Expert Opin Ther Targets 14(9):989–1003. doi: 10.1517/14728222.2010.510134
2. Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P, Omary B, Rich KM, Khosla C (2005) Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 12(4):469–475. doi: 10.1016/j.chembiol.2005.02.007
3. Delhase M, Kim SY, Lee H, Naiki-Ito A, Chen Y, Ahn ER, Murata K, Kim SJ, Lautsch N, Kobayashi KS, Shirai T, Karin M, Nakanishi M (2012) TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci USA 109(4):E177–E186. doi: 10.1073/pnas.1119296109
4. Folk JE (1980) Transglutaminases. Annu Rev Biochem 49:517–531. doi: 10.1146/annurev.bi.49.070180.002505
5. Folk JE, Park MH, Chung SI, Schrode J, Lester EP, Cooper HL (1980) Polyamines as physiological substrates for transglutaminases. J Biol Chem 255(8):3695–3700